By the use of genome-wide association method followed by prospective validation, it was found that the genotype of polypeptide N-acetylgalactosaminyltransferase 14 (GALNT14) could be used as a prognostic predictor for chemotherapy for hepatocellular carcinoma.11 A leading single nucleotide polymorphism (SNP) marker, rs9679162, was capable of predicting the time-to-tumor progression, overall survival (OS), and responses to chemotherapy. This evidence concerns the gene GALNT14 and neoplasm.